e-learning
resources
ERJ
2009
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Simvastatin and sildenafil combine to attenuate pulmonary hypertension
Zhao L., Sebkhi A., Ali O., Wojciak-Stothard B., Mamanova L., Yang Q., Wharton J., Wilkins M. R.
Source:
Eur Respir J 2009; 34: 948-957
Journal Issue:
October
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Zhao L., Sebkhi A., Ali O., Wojciak-Stothard B., Mamanova L., Yang Q., Wharton J., Wilkins M. R.. Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur Respir J 2009; 34: 948-957
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
Source: Eur Respir J 2010; 36: 800-807
Year: 2010
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Source: Eur Respir J 2007; 29: 469-475
Year: 2007
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: 1007-1010
Year: 2004
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Hemodynamic and anti-remodelling effect of the Rho kinase inhibitor Y-27632 in the monocrotaline pulmonary arterial hypertension rat model
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Targeting aquaporin 1 reverses hypoxia-induced pulmonary hypertension in mice
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Effect of POL6014, a protein epitope mimetic (PEM) neutrophil elastase inhibitor, in a model of monocrotaline (MCT)-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH).
Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Year: 2020
Blunted effects of rho-kinase inhibitor, fasudil, on pulmonary arterial pressure in Yak, a high altitude-adapted animal
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Hemodynamical effects of metformin and sildenafil in the treatment of experimental pulmonary hypertension
Source: International Congress 2019 – Pulmonary hypertension: clinical
Year: 2019
Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Sildenafil treatment for portopulmonary hypertension
Source: Eur Respir J 2006; 28: 563-567
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept